Skip to content
The Nexus
DossierENTITY

Blackstone Life Sciences

Coverage of Blackstone Life Sciences in the Nexus archive.

Earliest in view: May 27 · 14:33 UTCMost recent: May 27 · 14:33 UTC
Co-mentioned in this coverage
AstraZenecaorganization1FDAorganization1Apogee Therapeuticsorganization1Kaileraorganization1zumilokibarttopic1camizestranttopic1atopic dermatitistopic1
Recent coverage
  • HEALTHMay 27 · 14:33 UTCSTAT NEWS
    STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful

    The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.